肝脏影像报告和数据系统在肝细胞癌或整体恶性肿瘤的计算机断层扫描与磁共振图像分析中的准确性:一项系统综述
该系统综述检索2014至2018年数据库,纳入17项回顾性研究、2760例患者、3556个观察灶、2482个肝细胞癌,评估LI-RADS v2014和v2017各分类中经参考标准确认的肝细胞癌和整体恶性肿瘤百分比。结果显示LI-RADS分类级别升高,肝细胞癌和整体恶性肿瘤百分比增加;LR-5的肝细胞癌为94%、整体恶性肿瘤为97%,LR-M的整体恶性肿瘤为93%、肝细胞癌为36%。作者认为LR-2和LR-3中肝细胞癌百分比提示需要比当前推荐更积极的管理策略,并需前瞻性研究验证。
要点
- LR-5观察灶中94%为肝细胞癌、97%为整体恶性肿瘤。
- LR-M观察灶中93%为恶性肿瘤、36%为肝细胞癌。
- LR-2和LR-3的肝细胞癌百分比提示需要比当前推荐更积极的管理策略。
核心结论
- LI-RADS分类级别升高,经参考标准确认的肝细胞癌和整体恶性肿瘤百分比增加。
- LR-M观察灶中93%为恶性肿瘤、36%为肝细胞癌。
- LR-2和LR-3中肝细胞癌百分比提示需要比当前推荐更积极的管理策略。
- 需要前瞻性研究验证这些发现。
研究设计与样本
- 系统综述,检索MEDLINE、Embase、Cochrane CENTRAL和Scopus数据库2014年至2018年的研究。
- 纳入17项回顾性研究,共2760例患者、3556个观察灶、2482个肝细胞癌。
- 以病理、随访影像分析或治疗反应为参考标准,按观察灶评估LI-RADS v2014和v2017各分类中肝细胞癌和整体恶性肿瘤的百分比。
- 采用随机效应模型确定各LI-RADS分类的合并百分比,通过对数转换百分比的方差分析比较分类间差异。
- 使用QUADAS-2工具评估偏倚风险和适用性关注。
主要发现
- LR-5的肝细胞癌合并百分比为94%(95%CI 92%-96%),整体恶性肿瘤为97%(95%CI 95%-99%)。
- LR-4的肝细胞癌为74%(95%CI 67%-80%),整体恶性肿瘤为80%(95%CI 75%-85%)。
- LR-3的肝细胞癌为38%(95%CI 31%-45%),整体恶性肿瘤为40%(95%CI 31%-50%)。
- LR-2的肝细胞癌为13%(95%CI 8%-22%),整体恶性肿瘤为14%(95%CI 9%-21%)。
- LR-TIV的肝细胞癌为79%(95%CI 63%-89%),整体恶性肿瘤为92%(95%CI 77%-98%);LR-M的肝细胞癌为36%(95%CI 26%-48%),整体恶性肿瘤为93%(95%CI 87%-97%);LR-1组未发现恶性肿瘤;LR-2至LR-5组间肝细胞癌和整体恶性肿瘤百分比差异显著(P < .00001)。
关键数值与推荐
- LR-1:肝细胞癌和整体恶性肿瘤百分比原文未报告具体数值,原文写明未发现恶性肿瘤。
- LR-2:肝细胞癌13%(95%CI 8%-22%),整体恶性肿瘤14%(95%CI 9%-21%)。
- LR-3:肝细胞癌38%(95%CI 31%-45%),整体恶性肿瘤40%(95%CI 31%-50%)。
- LR-4:肝细胞癌74%(95%CI 67%-80%),整体恶性肿瘤80%(95%CI 75%-85%)。
- LR-5:肝细胞癌94%(95%CI 92%-96%),整体恶性肿瘤97%(95%CI 95%-99%);LR-TIV:肝细胞癌79%(95%CI 63%-89%),整体恶性肿瘤92%(95%CI 77%-98%);LR-M:肝细胞癌36%(95%CI 26%-48%),整体恶性肿瘤93%(95%CI 87%-97%)。
临床怎么用
- 作者认为LR-2和LR-3中肝细胞癌百分比提示需要比当前推荐更积极的管理策略。
- 作者提出需要前瞻性研究验证这些发现。
局限性
- 患者选择是最常影响偏倚风险的因素,源于验证偏倚和病例对照研究设计。
- 纳入研究均为回顾性研究。
- 需要前瞻性研究验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The Liver Imaging Reporting and Data System (LI-RADS) categorizes observations from imaging analyses of high-risk patients based on the level of suspicion for hepatocellular carcinoma (HCC) and overall malignancy. The categories range from definitely benign (LR-1) to definitely HCC (LR-5), malignancy (LR-M), or tumor in vein (LR-TIV) based on findings from computed tomography or magnetic resonance imaging. However, the actual percentage of HCC and overall malignancy within each LI-RADS category is not known. We performed a systematic review to determine the percentage of observations in each LI-RADS category for computed tomography and magnetic resonance imaging that are HCCs or malignancies. METHODS: We searched the MEDLINE, Embase, Cochrane CENTRAL, and Scopus databases from 2014 through 2018 for studies that reported the percentage of observations in each LI-RADS v2014 and v2017 category that were confirmed as HCCs or other malignancies based on pathology, follow-up imaging analyses, or response to treatment (reference standard). Data were assessed on a per-observation basis. Random-effects models were used to determine the pooled percentages of HCC and overall malignancy for each LI-RADS category. Differences between categories were compared by analysis of variance of logit-transformed percentage of HCC and overall malignancy. Risk of bias and concerns about applicability were assessed with the Quality Assessment of Diagnostic Accuracy Studies 2 tool. RESULTS: Of 454 studies identified, 17 (all retrospective studies) were included in the final analysis, consisting of 2760 patients, 3556 observations, and 2482 HCCs. The pooled percentages of observations confirmed as HCC and overall malignancy, respectively, were 94% (95% confidence interval [CI] 92%-96%) and 97% (95% CI 95%-99%) for LR-5, 74% (95% CI 67%-80%) and 80% (95% CI 75%-85%) for LR-4, 38% (95% CI 31%-45%) and 40% (95% CI 31%-50%) for LR-3, 13% (95% CI 8%-22%) and 14% (95% CI 9%-21%) for LR-2, 79% (95% CI 63%-89%) and 92% (95% CI 77%-98%) for LR-TIV, and 36% (95% CI 26%-48%) and 93% (95% CI 87%-97%) for LR-M. No malignancies were found in the LR-1 group. The percentage of HCCs and overall malignancies confirmed differed significantly among LR groups 2-5 (P < .00001). Patient selection was the most frequent factor that affected bias risk, because of verification bias and case-control study design. CONCLUSIONS: In a systematic review, we found that increasing LI-RADS categories contained increasing percentages of HCCs and overall malignancy based on reference standard confirmation. Of observations categorized as LR-M, 93% were malignancies and 36% were confirmed as HCCs. The percentage of HCCs found in the LR-2 and LR-3 categories indicate the need for a more active management strategy than currently recommended. Prospective studies are needed to validate these findings. PROSPERO number CRD42018087441.
引用
- van der Pol CB, Lim CS, Sirlin CB, et al. Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review. Gastroenterology. 2018. PMID: 30445016. doi:10.1053/j.gastro.2018.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。